Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported mixed results for the third quarter of 2023. The company also provided guidance for fiscal 2023. Net income attributable to shareholders was $1.93 billion or $0.93 per share in the September quarter, compared to $1.61 billion or $0.75 per share in the comparable period of 2022. […]
“Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported mixed results for the third quarter of 2023. The company also provided guidance for fiscal 2023. Net income attributable to shareholders was $1.93 billion or $0.93 per share in the September quarter, compared to $1.61 billion or $0.75 per share in the comparable period of 2022. […]
· October 27, 2023
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported mixed results for the third quarter of 2023. The company also provided guidance for fiscal 2023.
Net income attributable to shareholders was $1.93 billion or $0.93 per share in the September quarter, compared to $1.61 billion or $0.75 per share in the comparable period of 2022. Adjusted profit edged up to $2.0 per share in Q3 from $1.99 per share in the prior year period.
Third-quarter revenues decreased 2% from last year to $10.97 billion. Domestic revenues declined by 4%, while international revenues moved up 2%.
